• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Jordan Pharmaceuticals and Healthcare Report Q4 2008 - Product Image

Jordan Pharmaceuticals and Healthcare Report Q4 2008

  • Published: May 2008
  • Region: Jordan
  • 68 Pages
  • Business Monitor International


  • Dar Al Dawa (DAD)
  • GlaxoSmithKline
  • Hikma Pharmaceuticals
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

Jordan Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Jordan's pharmaceuticals and healthcare industry.

In the Business Environment Ratings Table for Q408, Jordan is placed in seventh position out of the 15 markets surveyed in the Middle East and Africa (MEA) region, with the table now including Kenya and Algeria. Jordan’s position worsened by one spot in relation to Q308, with Saudi Arabia improving its score and rising up the table. Nevertheless, Jordan has considerable commercial potential in regional terms, which is boosted by friendly relations with the West and growing Arab regional cooperation and high drug prices. While the overall market is small in global terms (less than US$340mn in 2007), expenditure on pharmaceuticals should grow at an average of 8.2% year-on-year (y-o-y) over the forecast period (2008-2012), topping US$502mn.

Jordanian pharmaceutical producers have been suffering from rising manufacturing costs, strong competition in the unbranded generics sector and the absence of price increases for drugs. A number of them recently posted – at best - mixed financial results. The leading producer, READ MORE >

Executive Summary 5
Jordan Pharmaceuticals And Healthcare Industry SWOT 6
Jordan Political SWOT 7
Jordan Economic SWOT 8
Jordan Business Environment Industry SWOT 9
Pharmaceutical Business Environment Ratings 10
Table: Middle East And Africa Pharmaceutical Business Environment Ratings 10
Limits To Potential Returns 11
Risks To Realisation Of Returns 11
Market Summary 12
Regulatory Regime13
Intellectual Property Developments 14
Counterfeit Pharmaceuticals 15
Pricing And Reimbursement Issues 16
International Collaboration 17
Industry Developments18
Epidemiology 18
Healthcare Sector 18
Medical Tourism 20
Domestic Pharmaceuticals Sector 20
Recent Domestic Company Activities 22
Foreign Companies 23
Retail Pharmacy Sector 23
Research And Development Sector 24
Clinical Trials 25
Medical Devices 25
Recent Medical Devices Market Developments 26
Table: Jordan Medical Device Market 27
Industry Forecast Scenario 28
Overall Market Forecasts 28
Table: Jordan - Drug Market Expenditure Indicators, 2004-2012 (JODmn unless otherwise indicated) 29
Key Growth Factors – Industry 30
Table: Jordan – Healthcare Expenditure Indicators, 2004-2012 (JODmn unless otherwise indicated) 30
Macroeconomic Forecast 31
Growth Slowdown And Increasing Fiscal Prudence 31
Table: Jordan – Economic Activity 33
Prescription Market Forecast 34
Table: Jordan – Prescription Market Indicators, 2004-2012 (JODmn unless otherwise stated) 35
OTC Market Forecast 36
Table: Jordan – OTC Market Indicators, 2004-2012 (JODn unless otherwise stated) 37
Patented Drugs Market Forecast 38
Table: Jordan – Patented Drugs Market Indicators, 2004-2012 (JODn unless otherwise indicated) 38
Generics Market Forecast 39
Table: Jordan – Generics Market Indicators, 2004-2012 (JODn unless otherwise indicated) 39
Import/Export Forecasts 40
Table: Jordan – Pharmaceutical Trade Indicators, 2004-2012 (US$mn) 41
Other Healthcare Data Forecasts 42
Table: Other Healthcare Indicators, 2004-2012 43
Key Risks To BMI’s Forecasts 43
Competitive Landscape44
Table: Top Six Drugmakers In Jordan, H107 44
Company Profiles45
Multinational Companies 45
Novartis 45
Sanofi-Aventis 46
Pfizer 47
GlaxoSmithKline 48
Merck & Co 49
Indigenous Manufacturers 50
United Pharmaceutical Manufacturers 50
Arab Pharmaceutical Manufacturers (APM) 51
Dar Al Dawa (DAD) 53
Hikma Pharmaceuticals 56
Jordanian Pharmaceutical Manufacturing (JPM) 60
Country Snapshot: Jordan Demographic Data 62
Section 1: Population 62
Table: Demographic Indicators, 2005-2030 62
Table: Rural/Urban Breakdown, 2005-2030 63
Section 2: Education And Healthcare 63
Table: Education, 2002-2005 63
Table: Vital Statistics, 2005-2030 63
Section 3: Labour Market And Spending Power 64
Table: Consumer Expenditure, 2000-2012 64
Table: Average Annual Manufacturing Wages, 2000-2012 64
BMI Forecast Modelling 65
How We Generate Our Pharmaceutical Industry Forecasts 65
Pharmaceutical Business Environment Ratings Methodology 65
Ratings Overview 66
Table: Pharmaceutical Business Environment Indicators 66
Weighting 67
Table: Weighting Of Components 67
Sources 67

-Merck & Co
-United Pharmaceutical Manufacturers
-Arab Pharmaceutical Manufacturers (APM)
-Dar Al Dawa (DAD)
-Hikma Pharmaceuticals
-Jordanian Pharmaceutical Manufacturing (JPM)

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos